|
41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases Clinical research trials and 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases. 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "4" Clinical Trials Conditions > 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases  41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
For Condition: Rheumatic Diseases
Status: No longer recruiting
Sponsor(s): National Center for Research Resources (NCRR) ,
Synopsis: Recently a non-toxic system for whole body hyperthermia (WBH) used at the University of Wisconsin has been shown to induce soluble tumor necrosis factor-receptor (sTNF-R) I and II when patients are heated systemically to 41.8C for 60 minutes. This observation might provide a biological basis for the therapeutic application of WBH to rheumatoid diseases, for which there is a positive anecdotal clinical experience. Inherent in the hypothesis which is the basis for this protocol is the concept that the induction of TNF receptors by WBH may induce a remission in patients with active rheumatoid arthritis. Beyond clinical response the biological endpoint for this investigation includes cytokine levels, TNF levels, sTNF-R levels and changes in cellular TNF receptors.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Parallel Assignment
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients are required to meet the criteria of the American College of Rheumatology (ACR)for rheumatoid arthritis. - Patients should be in functional class II, or III according to the criteria of the ACR. - All candidates must be unsuccessfully treated (lack of efficacy) with at least two of the following disease-modifying antirheumatic drugs: hydroxychloroquinine, oral or injectable gold, methotrexate, azathioprine, penicillamine, and sulfasalazine. - Patients receiving nonsteroidal antiinflammatory drugs (NSAIDs), corticosteroids (<= 10 mg per day), or both are eligible if the dosage has been stable for at least four weeks before treatment and remained so throughout the study and follow-up period (the use of narcotics for pain flares is allowed). - The necessary degree of disease activity at enrollment should be confirmed by a finding of 10 or more swollen joints, 12 or more tender joints, and one of the following two criteria: a Westergren erythrocyte sedimentation rate of at least 28 mm per hour or a serum C-reactive protein level of more than 2.0 mg per deciliter; or morning stiffness for at least 60 minutes. - Patients must have adequate bone marrow function, adequate liver function, adequate renal function, calcium and electrolytes. - Patients must have a dobutamine stress ECHO, or exercise cardiac MUGA, or exercise ECHO scan prior to entry and must fulfill certain criteria to be eligible. The spirit of the criteria are to rule out organic heart disease. - Respiratory status: Patients who have FEV1 of >= 60% of predicted, as well as a maximum voluntary volume (MVV) of >= 60% of predicted, and blood gases with a PO2 of >= 60 or oxygen saturation of >= 90% are eligible.
Total Enrollment:
Location and Contact Information:
K4/666 CSC 600 Highland Av
Madison, Wisconsin, 53792
United States
Additional Information:
Study ID Numbers: NCRR-M01RR03186-9943; M01RR03186
Study Start Date:
Record last reviewed: November 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000106
Other Rheumatic Diseases Studies:
1. Blood Component Collection from Patients with Rheumatic Disease and Healthy Volunteers
2. Study of Families with Twins or Siblings Discordant for Rheumatic Disorders
3. Improving Vocational Outcomes in Arthritis
4. 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
5. Health Beliefs and Health Behaviors Among Minorities with Rheumatic Diseases
Related Studies:
Other Rheumatic Diseases Clinical Trials
Other Wisconsin Clinical Trials
Other Madison Clinical Trials
41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
|
|
|
|
|
|
|
|
